Calcitonin oral - Enteris BioPharma/Tarsa Therapeutics

Drug Profile

Calcitonin oral - Enteris BioPharma/Tarsa Therapeutics

Alternative Names: Calcitonin-salmon [rDNA origin] delayed release tablets; Oral recombinant salmon calcitonin - Tarsa Therapeutics; Ostora; rsCT; Salmon calcitonin oral - Tarsa Therapeutics; sCT oral; TBRIA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unigene Laboratories
  • Developer Enteris BioPharma; Tarsa Therapeutics
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postmenopausal osteoporosis
  • No development reported Osteoarthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis(Combination therapy) in USA (PO)
  • 19 Oct 2015 Planned Prescription Drug User Fee Act (PDUFA) date for Postmenopausal osteoporosis in USA (PO) is 2016-05-30
  • 19 Oct 2015 The US FDA accepts NDA for oral calcitonin for Postmenopausal osteoporosis for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top